Researchers Develop Cellular Therapy for High-Risk COVID-19 Patients

Strategic Insights -

Researchers at Thomas Jefferson University in Philadelphia have made new findings in the development of cellular therapy for high-risk patients with COVID-19. The study, published in Blood Advances, explores the use of allogeneic SARS-CoV-2-specific cytotoxic T lymphocytes (CTLs) as a potential treatment for severe cases of the virus. According to the research, treatment with these CTLs may enhance cellular immunity in high-risk patients, providing a safe and direct mechanism for treatment.

Key Takeaways:

  • The study enrolled 30 high-risk ambulatory patients with COVID-19, with 12 receiving a single infusion of allogeneic SARS-CoV-2-specific CTLs.
  • The patients who received CTLs showed significant improvement in symptoms, with 88% and 99% viral elimination from baseline at 4 and 14 days after infusion, respectively.
  • The CTLs did not interfere with the development of endogenous anti-SARS-CoV-2 humoral or cellular responses.
  • T-cell receptor beta analysis showed persistence of donor-derived SARS-CoV-2-specific CTLs through the end of the 6-month follow-up period.
  • The study found that interventional patients showed consistent symptom improvement 2 to 3 days after infusion, while observational patients showed more variable improvement.
  • The researchers concluded that SARS-CoV-2-specific CTLs are a potentially feasible cellular therapy for high-risk patients with COVID-19.

Statistics:

  • 30 high-risk ambulatory patients with COVID-19 were enrolled in the phase 1 trial.
  • 12 interventional patients received a single infusion of allogeneic SARS-CoV-2-specific CTLs.
  • 88% and 99% viral elimination from baseline was observed at 4 and 14 days after infusion, respectively.
  • No dose-limiting toxicities were observed at any dosing level.
  • Patients who received CTLs showed significant improvement in symptoms, with 100% symptom resolution at 6 months.

Sources:

  • Safety and feasibility of third-party cytotoxic T lymphocytes for high-risk patients with COVID-19. Blood Advances, 2024, 8(15).
  • https://doi-org.sdpl.idm.oclc.org/10.1182/bloodadvances.2024013344
  • Our news editors report that more information may be obtained by contacting Dolores Grosso, 1Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States.